Igene Biotechnology, Inc.
Other OTCTotal Valuation
Igene Biotechnology, Inc. carries a market capitalization of 15,654.00, placing it among publicly traded companies globally. Its enterprise value stands at 22.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 15,654.00 |
| Enterprise Value | 22.71M |
Share Statistics
Igene Biotechnology, Inc. currently has 1.57B shares outstanding.
| Shares Outstanding | 1.57B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3,256.69, and the price-to-book ratio stands at -0.40.
| PE Ratio | N/A |
| PS Ratio | 3,256.69 |
| PB Ratio | -0.40 |
| P/TBV Ratio | -3.24 |
| P/FCF Ratio | -9.21 |
| P/OCF Ratio | -9.30 |
Enterprise Valuation
The EV/Sales ratio of 4,727.62 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 201.89 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4,727.62 |
| EV / EBITDA | 421.30 |
| EV / EBIT | 201.89 |
| EV / FCF | N/A |
Financial Position
Igene Biotechnology, Inc. maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -156.55, indicating conservative leverage, while an interest coverage ratio of -7.09 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.15 |
| Quick Ratio | 1.15 |
| Debt / Equity | -156.55 |
| Debt / EBITDA | -16.02 |
| Interest Coverage | -7.09 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -52.27 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Income Statement
Over the trailing twelve months, Igene Biotechnology, Inc. generated 4,804.00 in revenue and converted that into -2.37M in net income, yielding earnings per share of 0.00. EBITDA reached -457,775.00, while operating income came in at -596,767.00.
| Revenue | 4,804.00 |
| Gross Profit | 40,847.00 |
| Operating Income | -596,767.00 |
| Pretax Income | N/A |
| Net Income | -2.37M |
| EBITDA | -457,775.00 |
| EBIT | -596,767.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Igene Biotechnology, Inc. holds 269,290.00 in cash and equivalents against 7.34M in total debt, resulting in a net debt position of 7.07M. Total book value stands at -39.20M, with working capital of 312,110.00 providing operational flexibility.
| Cash & Cash Equivalents | 269,290.00 |
| Total Debt | 7.34M |
| Net Debt | 7.07M |
| Equity (Book Value) | -39.20M |
| Book Value Per Share | -0.03 |
| Working Capital | 312,110.00 |
Cash Flow
Igene Biotechnology, Inc. produced -1.68M in operating cash flow over the past twelve months. After subtracting 16,623.00 in capital expenditures, free cash flow totaled -1.67M - equivalent to 0.00 per share.
| Operating Cash Flow | -1.68M |
| Capital Expenditures | 16,623.00 |
| Free Cash Flow | -1.67M |
| FCF Per Share | 0.00 |
Margins
Igene Biotechnology, Inc. operates with a gross margin of 850.27, reflecting its pricing power and cost economics. The operating margin of -12,422.29 and net profit margin of -49,414.70 provide insight into operational efficiency.
| Gross Margin | 850.27 |
| Operating Margin | -12,422.29 |
| Pretax Margin | N/A |
| Profit Margin | -49,414.70 |
| EBITDA Margin | -9,529.04 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -10.86 |
Scores
Igene Biotechnology, Inc. posts an Altman Z-Score of -22.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -22.86 |